These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21722683)

  • 1. Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes.
    Rosenkrands I; Vingsbo-Lundberg C; Bundgaard TJ; Lindenstrøm T; Enouf V; van der Werf S; Andersen P; Agger EM
    Vaccine; 2011 Aug; 29(37):6283-91. PubMed ID: 21722683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.
    Wang D; Christopher ME; Nagata LP; Zabielski MA; Li H; Wong JP; Samuel J
    J Clin Virol; 2004 Dec; 31 Suppl 1():S99-106. PubMed ID: 15567101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
    Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
    Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.
    Baldwin SL; Shaverdian N; Goto Y; Duthie MS; Raman VS; Evers T; Mompoint F; Vedvick TS; Bertholet S; Coler RN; Reed SG
    Vaccine; 2009 Oct; 27(43):5956-63. PubMed ID: 19679214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.
    Madhun AS; Haaheim LR; Nilsen MV; Cox RJ
    Vaccine; 2009 Dec; 27(52):7367-76. PubMed ID: 19781678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
    Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
    Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines.
    Liu H; Bungener L; ter Veer W; Coller BA; Wilschut J; Huckriede A
    Vaccine; 2011 Mar; 29(11):2037-43. PubMed ID: 21251903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine.
    Adler-Moore J; Munoz M; Kim H; Romero J; Tumpey T; Zeng H; Petro C; Ernst W; Kosina S; Jimenez G; Fujii G
    Vaccine; 2011 Jun; 29(27):4460-8. PubMed ID: 21545821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
    Baras B; de Waal L; Stittelaar KJ; Jacob V; Giannini S; Kroeze EJ; van den Brand JM; van Amerongen G; Simon JH; Hanon E; Mossman SP; Osterhaus AD
    Vaccine; 2011 Mar; 29(11):2120-6. PubMed ID: 21238573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
    Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
    Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS; Lee KA; Lee JY; Kang MH; Song YC; Baek DJ; Kim S; Kang CY
    Vaccine; 2011 Jan; 29(3):417-25. PubMed ID: 21087689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.